Human norovirus deactivator

Abstract

To provide a human norovirus inactivating agent and a sanitary material excellent in human norovirus inactivating effect.SOLUTION: A human norovirus deactivator comprising: (a) ethanol; and (b) at least two acids selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid, wherein the human norovirus deactivator has a pH of 1 to 6.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to an agent for inactivating human norovirus. [Background technology]

[0002] Some viruses can infect humans, and virus inactivators have been used to prevent infection.

[0003] In recent years, cases of infectious gastroenteritis or food poisoning caused by viruses such as human norovirus have been occurring frequently throughout the year, with peak occurrence occurring between November and March. Human norovirus, in particular, is a non-enveloped RNA virus classified in the Caliciviridae family and Norovirus genus, and is highly resistant to alcohol (ethanol, isopropanol, etc.), heat, acidity (gastric acid, etc.), and dryness. The incubation period is thought to be one to two days, and the main symptoms are nausea, vomiting, and diarrhea, but may also include abdominal pain, headache, fever, chills, muscle pain, sore throat, and fatigue.

[0004] Since human norovirus cannot be cultured, the inactivation of virus inactivating agents has been evaluated using closely related surrogate viruses, feline calicivirus and murine norovirus. For example, the inactivation of feline calicivirus and murine norovirus was evaluated under conditions of protein load, and it was speculated that a formulation effective against both surrogate viruses would also be effective against human norovirus (see, for example, Patent Document 1).

[0005] Although acidic ethanol preparations have been reported to be highly effective in inactivating surrogate viruses, some acidic alcohol preparations on the market are not effective against human norovirus. Therefore, a composition that is effective against surrogate viruses may not necessarily be effective against human norovirus, and a composition that is ineffective against surrogate viruses may not necessarily be ineffective against human norovirus.

[0006] In recent years, the development of methods for propagating human norovirus, such as growing the virus in intestinal epithelial cells prepared from human iPS cell lines, has made it possible to directly evaluate the ability of acidic alcohol preparations to inactivate human norovirus (see, for example, Non-Patent Document 1). [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Japanese Patent Application Publication No. 2018-197205 [Non-patent literature]

[0008] [Non-Patent Document 1] Sato, S., Matsumoto, N., Hisaie, K. et al.Alcohol abrogates human norovirus infectivity in a pH-dependent manner.Sci Rep 10,15878(2020). <url>https: / / doi.org / 10.1038 / s41598-020-72609-z Summary of the Invention [Problem to be solved by the invention]

[0009] There is a demand for a human norovirus inactivating agent that has an excellent human norovirus inactivating effect, and for sanitary materials that contain the human norovirus inactivating agent.

[0010] The present invention has been made in view of the above-mentioned current situation, and an object of the present invention is to provide a human norovirus inactivating agent and a sanitary material that have excellent human norovirus inactivation effects. [Means for solving the problem]

[0011] That is, the present invention (1) is a human norovirus inactivating agent characterized by comprising (a) ethanol and (b) at least two acids selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid, and having a pH of 1 to 6.

[0012] "Human norovirus inactivators" refer to substances used to inactivate human norovirus. However, because they can be used to inactivate human norovirus, a type of non-enveloped virus that is highly drug-resistant, they can often also be used to inactivate other viruses.

[0013] The human norovirus inactivating agent of the present invention (1) contains (a) ethanol and (b) at least two acids selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid, and has a pH of 1 to 6, thereby exhibiting excellent human norovirus inactivation effects. In this specification, the pH is a value measured by the method described in the Examples. At such a pH, the agent can exert its human norovirus inactivation effect while more sufficiently preventing rough skin, such as rough hands, and further reducing the impact on the target object.

[0014] The reason why the human norovirus inactivating agent of the present invention (1) can exhibit such an excellent effect of inactivating human norovirus is not entirely clear, but is thought to be as follows. Viral infection and replication occur when the virus adsorbs to and invades the surface of a host cell, replicates the viral genome, synthesizes viral proteins within the cell, and then forms viral particles that are released outside the host cell. Although the details of the mechanism of virus inactivation are unclear, it is thought that ethanol and the acid of the present invention either denature the surface of the viral particles or destroy the viral particles themselves, thereby inhibiting the virus from adsorbing to and invading host cells.

[0015] The present invention (2) relates to the human norovirus inactivating agent of the present invention (1), wherein the mass proportion of the (a) ethanol is 25 mass % or more. This makes it possible to achieve a more excellent human norovirus inactivation effect.

[0016] The present invention (3) relates to the human norovirus inactivating agent of the present invention (1) or (2), wherein the mass proportion of the (a) ethanol is 90 mass % or less.

[0017] The present invention (4) is the human norovirus inactivating agent according to any one of the present inventions (1) to (3), wherein the total mass proportion of the acid (b) is 0.3 mass % or more. This makes it possible to achieve a more excellent human norovirus inactivation effect.

[0018] The present invention (5) is the human norovirus inactivating agent according to any one of the present inventions (1) to (4), wherein the total mass proportion of the acid (b) is 2 mass % or less. The human norovirus inactivating agent of the present invention (5) exhibits a high virus inactivating effect against human norovirus while sufficiently preventing stickiness.

[0019] The present invention (6) also relates to a sanitary material containing the human norovirus inactivating agent of any one of the present inventions (1) to (5). The human norovirus inactivating agent of the present invention has an excellent human norovirus inactivating effect, and therefore, by using sanitary materials containing such a human norovirus inactivating agent, human norovirus infection can be prevented. [Effects of the Invention]

[0020] The human norovirus inactivating agent and sanitary material of the present invention can exhibit excellent human norovirus inactivation effects. DETAILED DESCRIPTION OF THE INVENTION

[0021] The present invention will be described in detail below. However, the present invention is not limited to the following embodiments, and can be applied by making appropriate modifications within the scope of the present invention.

[0022] <Human norovirus inactivator> The human norovirus inactivating agent of the present invention comprises (a) ethanol and (b) at least two acids selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid, and has a pH of 1 to 6.

[0023] (ethanol) The human norovirus inactivating agent of the present invention contains (a) ethanol. In 100% by mass of the human norovirus inactivating agent of the present invention, the mass proportion of (a) ethanol is preferably 25% by mass or more, more preferably 30% by mass or more, even more preferably 35% by mass or more, and particularly preferably 40% by mass or more. The mass proportion of the (a) ethanol is preferably 90 mass % or less.

[0024] (acid) The human norovirus inactivating agent of the present invention contains (b) at least two acids selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid. As the acid, from the viewpoint of improving the smell of the human norovirus inactivating agent, gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, and phosphoric acid are preferred, gluconic acid, fumaric acid, lactic acid, and succinic acid are more preferred, and gluconic acid, fumaric acid, and lactic acid are even more preferred. From the viewpoint of improving the human norovirus inactivating effect, gluconic acid and fumaric acid are particularly preferred.

[0025] The human norovirus inactivating agent of the present invention preferably includes (b) a combination of acids, for example, a combination of gluconic acid and lactic acid, a combination of fumaric acid and lactic acid, a combination of lactic acid and malic acid, a combination of lactic acid and succinic acid, a combination of lactic acid and citric acid, a combination of lactic acid and phosphoric acid, a combination of gluconic acid and fumaric acid, a combination of gluconic acid and malic acid, a combination of gluconic acid and succinic acid, a combination of gluconic acid and citric acid, a combination of gluconic acid and phosphoric acid, a combination of fumaric acid and malic acid, a combination of fumaric acid and succinic acid, a combination of malic acid and succinic acid, or a combination of succinic acid and citric acid. Among these, it is more preferable that the human norovirus inactivating agent of the present invention contains a combination of gluconic acid and lactic acid, a combination of fumaric acid and lactic acid, a combination of lactic acid and succinic acid, a combination of lactic acid and phosphoric acid, a combination of gluconic acid and fumaric acid, a combination of gluconic acid and malic acid, a combination of gluconic acid and succinic acid, a combination of gluconic acid and citric acid, a combination of gluconic acid and phosphoric acid, a combination of fumaric acid and malic acid, a combination of fumaric acid and succinic acid, a combination of malic acid and succinic acid, or a combination of succinic acid and citric acid.

[0026] In terms of improving the human norovirus inactivation effect, the total mass proportion of the (b) acid in 100% by mass of the human norovirus inactivating agent of the present invention is preferably 0.1% by mass or more, more preferably 0.3% by mass or more, even more preferably 0.5% by mass or more, and particularly preferably 1% by mass or more. From the viewpoint of further reducing the stickiness of the human norovirus inactivating agent, the total mass proportion of the (b) acid is preferably 2 mass % or less, and more preferably 1.5 mass % or less. The total mass proportion of the (b) acid is the total mass proportion of two or more of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid contained as the (b) acid in the human norovirus inactivating agent of the present invention.

[0027] Furthermore, the human norovirus inactivating agent of the present invention preferably contains, as (b) the acid, for example, lactic acid and / or gluconic acid as an essential component, and more preferably contains lactic acid as an essential component.

[0028] When the human norovirus inactivating agent of the present invention essentially contains lactic acid, the mass proportion of lactic acid in 100% by mass of the human norovirus inactivating agent of the present invention is preferably 0.1% by mass or more, more preferably 0.2% by mass or more, and even more preferably 0.5% by mass or more. The upper limit of the mass proportion of lactic acid is not particularly limited, but it is preferably, for example, 2 mass % or less. This makes the human norovirus inactivating agent of the present invention easy to handle while still exhibiting excellent human norovirus inactivation effects.

[0029] It is also preferred that the human norovirus inactivating agent of the present invention essentially contains, as the acid (b), gluconic acid, for example. When the human norovirus inactivating agent of the present invention essentially contains gluconic acid, the mass proportion of gluconic acid in 100% by mass of the human norovirus inactivating agent of the present invention is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and more preferably 0.15% by mass or more. The upper limit of the mass proportion of gluconic acid is not particularly limited, but is preferably, for example, 2 mass% or less, more preferably 1 mass% or less, and from the viewpoint of reducing stickiness of the human norovirus inactivating agent of the present invention, even more preferably 0.5 mass% or less. This makes the human norovirus inactivating agent of the present invention easy to handle while still exhibiting excellent human norovirus inactivation effects.

[0030] For example, the human norovirus inactivating agent of the present invention preferably contains, based on 100% by mass of the human norovirus inactivating agent, 0.2% by mass or more and 1.5% by mass or less of lactic acid and 0.3% by mass or more and 2.5% by mass or less of lactic acid and at least one acid selected from the group consisting of gluconic acid, fumaric acid, malic acid, succinic acid, citric acid, and phosphoric acid in a total amount of 0.3% by mass or more and 2.5% by mass or less. It is particularly preferred that the human norovirus inactivating agent of the present invention contains 2% by mass or less of lactic acid and at least one acid selected from the group consisting of gluconic acid, fumaric acid, malic acid, succinic acid, citric acid, and phosphoric acid in a total amount of 2% by mass or less. This ensures that the human norovirus inactivating agent of the present invention has well-balanced and excellent performance.

[0031] Furthermore, for example, the human norovirus inactivating agent of the present invention preferably contains, based on 100% by mass of the human norovirus inactivating agent, 0.1% by mass or more and 0.5% by mass or less of gluconic acid and 0.3% by mass or more in total of gluconic acid and at least one acid selected from the group consisting of fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid, which allows the human norovirus inactivating agent of the present invention to achieve both reduced stickiness and a human norovirus inactivating effect.

[0032] Furthermore, for example, the human norovirus inactivating agent of the present invention preferably contains, as (b) acid, 0.05% by mass or more and 0.5% by mass or less of gluconic acid, and 0.3% by mass or more and 2% by mass or less of gluconic acid and at least one acid selected from the group consisting of lactic acid, fumaric acid, malic acid, succinic acid, citric acid, and phosphoric acid in total, based on 100% by mass of the human norovirus inactivating agent. In particular, it is more preferable that the human norovirus inactivating agent of the present invention contains (a) ethanol in an amount of 40% by mass or more and 90% by mass or less. Furthermore, the human norovirus inactivating agent of the present invention more preferably has a pH of 2 to 5.5.

[0033] Furthermore, for example, it is particularly preferred that the human norovirus inactivating agent of the present invention contains, based on 100% by mass of the human norovirus inactivating agent, (a) 40% by mass or more and 90% by mass or less of ethanol, (b) 0.05% by mass or more and 0.5% by mass or less of gluconic acid as an acid, and 0.3% by mass or more and 2% by mass or less in total of gluconic acid and at least one acid selected from the group consisting of lactic acid, fumaric acid, malic acid, succinic acid, citric acid, and phosphoric acid, and has a pH of 2 to 5.5. This allows the human norovirus inactivating agent of the present invention to have well-balanced and excellent performance.

[0034] In the human norovirus inactivating agent of the present invention, the mass ratio of (a) ethanol to (b) acid ((a) / (b)) is preferably 1-500, more preferably 3-450, even more preferably 5-400, and particularly preferably 10-300.

[0035] (inorganic salts) The human norovirus inactivating agent of the present invention may further contain an inorganic salt. Examples of inorganic salts include magnesium sulfate, iron sulfate, copper sulfate, potassium sulfate, potassium bromide, sodium iodide, sodium sulfite, potassium sulfite, sodium nitrate, ammonium nitrate, sodium nitrite, potassium nitrite, ammonium nitrite, sodium thiocyanate, and the like, and one or more of these can be used. Inorganic salts usually exist in the form of cations and anions in the human norovirus inactivating agent.

[0036] When the human norovirus inactivating agent of the present invention contains an inorganic salt, the mass proportion of the inorganic salt is preferably 0.001 to 5 mass % relative to 100 mass % of the human norovirus inactivating agent of the present invention.

[0037] (pH adjuster) The human norovirus inactivating agent of the present invention may further contain a pH adjuster, such as an acidic agent such as sulfuric acid, hydrochloric acid, or sulfamic acid, or an alkaline agent such as sodium hydroxide, potassium hydroxide, sodium silicate, or potassium silicate. The amount of acidic agent or alkaline agent can be adjusted appropriately depending on the desired pH.

[0038] (water) The human norovirus inactivating agent of the present invention preferably further contains water. The water is not particularly limited, but examples include tap water, distilled water, purified water, pure water, and ion-exchanged water. The mass concentration of water in the human norovirus inactivating agent of the present invention is preferably 0.1 to 90 mass%, more preferably 1 to 80 mass%, even more preferably 3 to 70 mass%, and particularly preferably 5 to 60 mass%.

[0039] (surfactant) The human norovirus inactivating agent of the present invention may further contain a surfactant. Examples of the surfactant include anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants, and one or more of these can be used. In the human norovirus inactivating agent of the present invention, the concentration of the surfactant is preferably 10% by mass or less. The concentration of the surfactant is more preferably 1% by mass or less.Moreover, it is even more preferable that the human norovirus inactivating agent of the present invention does not contain a surfactant. When multiple types of surfactants are used, the concentration of the surfactant is the total concentration of the multiple types of surfactants.

[0040] (alcohol other than ethanol) The human norovirus inactivating agent of the present invention may further contain an alcohol other than ethanol. Examples of alcohols other than ethanol include lower alcohols having 1, and 3 to 5 carbon atoms, and one or more of these may be used. In 100% by mass of the human norovirus inactivating agent of the present invention, the concentration of alcohols other than ethanol is preferably 40% by mass or less. The concentration of alcohols other than ethanol is more preferably 20% by mass or less, and even more preferably 10% by mass or less. Furthermore, it is particularly preferred that the human norovirus inactivating agent of the present invention does not contain alcohols other than ethanol. When multiple types of alcohols other than ethanol are used, the concentration of the alcohol other than ethanol is the total concentration of the multiple types of alcohols other than ethanol.

[0041] (organic solvents other than alcohol) The human norovirus inactivating agent of the present invention may further contain an organic solvent other than alcohol, but it is preferable that the concentration of the organic solvent other than alcohol is 40 mass% or less in 100 mass% of the human norovirus inactivating agent of the present invention. The concentration of the organic solvent other than alcohol is more preferably 20% by mass or less, and even more preferably 10% by mass or less. It is particularly preferred that the human norovirus inactivating agent of the present invention contains no organic solvent other than alcohol. When a plurality of types of organic solvents other than alcohol are used, the concentration of the organic solvent other than alcohol is the total concentration of the plurality of types of organic solvents other than alcohol.

[0042] (Other ingredients) The human norovirus inactivating agent of the present invention may contain other ingredients such as solubilizing agents, thickeners, enzymes, fragrances, and coloring dyes in addition to the above-mentioned ingredients. The mass proportion of other components in 100% by mass of the human norovirus inactivating agent of the present invention is preferably 10% by mass or less, and more preferably 1% by mass or less.

[0043] (pH) The human norovirus inactivating agent of the present invention has a pH of 1-6. From the viewpoint of more adequately preventing rough skin such as rough hands and further reducing the impact on the target object of use, the pH is preferably 2 or higher, more preferably 2.5 or higher, and even more preferably greater than 3. From the viewpoint of further improving the human norovirus inactivation effect, the pH is preferably 5.5 or less, more preferably 5 or less, and even more preferably 4.5 or less. As mentioned above, the pH can be adjusted using a pH adjuster. pH is measured at 25°C using the method described in the Examples.

[0044] <Application> Next, uses of the human norovirus inactivating agent of the present invention will be described. As will be shown in the Examples below, the human norovirus inactivating agent of the present invention can exhibit an inactivating effect on human norovirus, and can be suitably used for inactivating human norovirus. The human norovirus inactivating agent of the present invention also exhibits a high virus inactivating effect against enveloped viruses such as influenza viruses and coronaviruses, which have lower drug resistance than human noroviruses.

[0045] The human norovirus inactivating agent of the present invention may be added to a disinfectant. Furthermore, the human norovirus inactivating agent of the present invention or the disinfectant of the present invention may be used in sanitary materials. The human norovirus inactivating agent of the present invention exhibits excellent virus inactivation effects against various viruses including human norovirus, and therefore, by using a disinfectant containing such a human norovirus inactivating agent, viral infection can be sufficiently prevented.

[0046] The sanitary material of the present invention is not particularly limited, but examples thereof include masks, disposable gloves, disposable dish towels, tissue paper, wet tissues, and the like.

[0047] The human norovirus inactivating agent of the present invention may be added to a cleaning agent. The human norovirus inactivating agent of the present invention, and a disinfectant or cleaning agent containing the human norovirus inactivating agent of the present invention, are preferably used by being packed in a pump bottle or spray bottle. [Example]

[0048] Examples are provided below to more specifically illustrate the present invention, but the present invention is not limited to these examples. In the examples, "%" means "% by mass" unless otherwise specified. In the tables of the examples, the mass percentage of each component is the mass percentage (% by mass) of the pure content, and the total of all components is 100% by mass.

[0049] (Examples 1 to 32) and (Comparative Examples 1 to 2) Human norovirus inactivating agents according to Examples 1 to 32 and Comparative Examples 1 and 2 were prepared according to the formulations shown in Tables 1 to 3. In addition, the manufacturers of the compounds in Tables 1 to 3 are as follows:

[0050] <(a) Ethanol> Ethanol: Ethanol (99.5%) manufactured by Yoneyama Pharmaceutical Co., Ltd. (b) Acid according to the present invention Gluconic acid: 50% gluconic acid solution manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. Fumaric acid: Fujifilm Wako Pure Chemical Industries, Ltd. Lactic acid: Fujifilm Wako Pure Chemical Industries, Ltd. Malic acid: DL-malic acid manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. Succinic acid: Fujifilm Wako Pure Chemical Industries, Ltd. Citric acid: Citric acid manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. Phosphoric acid: Fujifilm Wako Pure Chemical Industries, Ltd.

[0051] <(b)' Acids other than the acids according to the present invention> Acetic acid: acetic acid manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. Ferulic acid: Ferulic acid manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.

[0052] <Alcohol other than ethanol> Isopropanol: 2 - propanol manufactured by FUJIFILM Wako Pure Chemical Corporation

[0053] <Organic solvent other than alcohol> Propylene glycol: Propylene glycol manufactured by FUJIFILM Wako Pure Chemical Corporation

[0054] <Surfactant> Polysorbate 60: Polysorbate 60 manufactured by NOF Corporation

[0055] <pH adjuster> Sodium hydroxide: 50 w / v% sodium hydroxide solution manufactured by FUJIFILM Wako Pure Chemical Corporation Hydrochloric acid: Hydrochloric acid manufactured by FUJIFILM Wako Pure Chemical Corporation

[0056]

Table 1

[0057]

Table 2

[0058]

Table 3

[0059] <Inactivation effect on human norovirus> [Preparation of human norovirus solution] Nine parts of PBS were added to and mixed with one part of feces collected from a human norovirus - positive patient. After centrifugation at 10,000 g for 5 minutes at 4°C, the supernatant was collected and filtered through a 0.22 μm membrane filter to be used as the human norovirus solution.

[0060] [Procedure for inactivating human norovirus using a human norovirus inactivator] Nine parts of a human norovirus inactivator were added to one part of a human norovirus solution diluted 10 times with PBS, mixed, and allowed to act for one minute. After the action, the solution was diluted 10-fold with culture medium to stop the action of the human norovirus inactivator.

[0061] [Human norovirus culture] Two 96-well flat-bottom plates were inoculated with a mixture of the inactivated human norovirus inactivator and human norovirus solution onto human iPS cell-derived intestinal epithelial cells and cultured for 3 hours. The cells were then washed twice with medium and 100 μL of culture medium was added. The cell monolayer and supernatant from one plate were harvested, while the other plate was cultured for an additional 69 hours, for a total of 72 hours.

[0062] [Quantitation of human norovirus genome quantity] Monolayers of human iPS cell-derived intestinal epithelial cells 3 hours (3 hpi) and 72 hours (72 hpi) post-infection and RNase-treated supernatants were dissolved in phenol extraction reagent, and quantitative RT-PCR was performed using a human norovirus-specific primer / probe set and the Luna® Universal Probe One-Step RT-qPCR Kit (Biolabs, E3006) according to the manufacturer's instructions to calculate the human norovirus genome amount.

[0063] ·control The human norovirus inactivation agent, which had been diluted 10-fold with culture medium, was mixed with the human norovirus liquid at a ratio of 99:1. The mixture was inoculated onto human iPS cell-derived intestinal epithelial cells seeded in a 96-well flat-bottom plate, and two plates were created. One plate was cultured for 3 hours, and the other for 72 hours. Monolayers and supernatants of human iPS cell-derived intestinal epithelial cells 3 hours (3 hpi) and 72 hours (72 hpi) post-infection were dissolved in phenol extraction reagent, and quantitative RT-PCR was performed using a human norovirus-specific primer / probe set and the Luna® Universal Probe One-Step RT-qPCR Kit (Biolabs, E3006) according to the manufacturer's instructions to calculate the amount of human norovirus genome.

[0064] [Evaluation of human norovirus inactivation] The genome amounts of human norovirus at 3 hpi and 72 hpi were compared to evaluate the degree of human norovirus inactivation. The evaluation criteria are as follows: ◎: The human norovirus genome was reduced to below the detection limit at 3 hpi and 72 hpi (inactivated by destroying the virus particles). ○: The viral genome amounts at 3 hpi and 72 hpi were above the detection limit, but were equivalent, and the increase in the genome amount was suppressed (the virus particles were inactivated by denaturing their surfaces). △: The genome amount at 72 hpi increased compared to 3 hpi, but the increase was less than the control (some of the virus was inactivated). ×: The genome amount at 72 hpi is equal to or greater than that of the control compared to 3 hpi (the virus was not inactivated) If the evaluation of human norovirus inactivation is good or better, the effect of inactivating human norovirus is good.

[0065] <Sticky> Using a trigger sprayer T-95 Mist Trigger (Canyon Co., Ltd.) with a spray volume of approximately 1 mL per spray, the human norovirus inactivator was sprayed once onto a polypropylene plate (Nippon Test Panel Co., Ltd.) from a distance of approximately 25 cm, and then allowed to dry. The above process was repeated three times. Thereafter, the plastic surface was touched with hands and subjected to a sensory evaluation. The evaluation criteria are as follows: ◎: No residual ingredients are felt ○: I can feel some residual ingredients, but it's not sticky. △: Slightly sticky ×: Clearly sticky If the stickiness rating is △ or higher, the stickiness rating is good.

[0066] <Smell> After storing the human norovirus inactivation agent at 45°C for 30 days or more, a sensory evaluation was conducted to determine any odors other than ethanol. ◎: No unpleasant odor other than ethanol ○: There is an odor other than ethanol, but it is not unpleasant. △: A slightly unpleasant smell other than ethanol is detected ×: There is a distinct unpleasant smell other than ethanol. If the odor rating is fair or better, the odor rating is good.

[0067] Tables 1 to 3 reveal that the human norovirus inactivating agents according to the examples exhibit excellent human norovirus inactivation effects. Furthermore, the human norovirus inactivating agents according to the examples are less sticky and have less odor, making them highly suitable for a variety of uses.< / url>

Claims

1. (a) ethanol; (b) at least two acids selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid; A human norovirus inactivating agent having a pH of 1 to 6.

2. The human norovirus inactivating agent according to claim 1 , wherein the mass proportion of the (a) ethanol is 25 mass% or more.

3. The human norovirus inactivating agent according to claim 1 or 2, wherein the mass proportion of the (a) ethanol is 90 mass% or less.

4. The human norovirus inactivating agent according to claim 1 or 2, wherein the total mass proportion of the acid (b) is 0.3 mass% or more.

5. The human norovirus inactivating agent according to claim 1 or 2, wherein the total mass proportion of the acid (b) is 2 mass% or less.

6. A sanitary material comprising the human norovirus inactivating agent according to claim 1 or 2.

Images